Researchers at the University of California San Diego will soon launch the second-phase clinical trial of a promising gene therapy for Alzheimer’s disease, one that attempts to boost the survival and functioning of brain cells.

The scientists are seeking qualified study volunteers.

In earlier animal and human safety trials, a gene therapy drug called CERE-110 was injected into patients’ brains, initially via modified skin cells, later using a harmless viral carrier. CERE-110 carries a gene that promotes long-term production of nerve growth factor (NGF), a natural molecule that helps brain cells live and function longer.

“NGF is known to support the survival and function of the neurons that deteriorate in Alzheimer’s disease,” said Dr. Michael Rafii, an assistant professor in UCSD’s department of neurosciences. “These neurons produce a chemical called acetylcholine, which is important in memory and cognitive function. The hope is that restoration of this system’s function may improve memory in Alzheimer’s patients.”

Read the entire article:  Clinical trial of Alzheimer’s gene therapy moves forward – SignOnSanDiego.com

Neurons in the brain – illustration
Credit: Benedict Campbell. Wellcome Images
images@wellcome.ac.uk